Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSELR plus standard therapy versus placebo plus standard therapy for pediatric IgA nephropathy
ChiCTR2400083736Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of total saponins from rehmannia leaves in IgA nephropathy (IgAN) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Urinary protein quantification, Frequency of 50% reduction in urine protein and 1 more. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
total saponins from rehmannia leaves
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2400083736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083736.